Angiography within anterior imaging


It is important with corneal angiography to remember that every patient is different so your technique might very slightly from patient to patient.

Reviewed by Dr Martin Hodson

The purpose of corneal angiography is to locate the blood vessels within the cornea and evaluate their condition. The ‘gold standard’ technique used to do this is anterior segment colour imaging, but it is not straightforward and the images acquired are often of poor quality.

Consequently, Dr Martin Hodson of the St Paul’s Eye Unit, Liverpool, started using dyes to improve the imaging of corneal neovascularisation. After seven years of experience he is well placed to share his expertise and gave a presentation entitled ‘Angiography Within Anterior Imaging’ during the joint Ophthalmic Imaging Association and Ophthalmic Photography Netherlands photographic and imaging session at the European Society of Ophthalmology meeting in Barcelona in June.


Colour imaging

When colour images are required, Mr Hodson uses a Topcon system: a diffuse beam is used, magnification is set at 10 x and the light is set at a 45° angle. The use of the Heidelberg Engineering system when dye has been injected is primarily because it has the capability to record video, which improves the likelihood of recording a useful image compared with a one-shot technique.


Dye angiography

When more in-depth images are required, indocyanine green (ICG) and fluorescein dyes are introduced. There are various considerations, one of which is which lens to use.

The 30° lens gives the best view of the corneal shoulder and the limbus, but for work on the cornea itself the blue OCT lens is best due to its ability to flatten the image, bringing more of the vessels into focus.

It is also important to get the focus right, which can of course be difficult because the cornea is completely transparent. Mr Hodson gets the best results by setting the focus to 34 D.

Lastly, it is important to ensure the eyelids do not interfere with the picture. Many patients find it hard to keep their eyes open when confronted with a bright light and it is likely that it will be necessary for the technician to physically hold the eyelids out of the way.

Once the dye has been injected and has been seen to appear within the eyelids, a 30-second video is started.

Figure 1 compares images taken using the different techniques. There is much more detail apparent using ICG compared with the (good) gold standard colour image, because use of the dye in conjunction with infrared light allows one to see past the corneal scarring.

The ‘early’ (30 seconds) and ‘late’ (about 2–3 minutes) fluoroscein images allow the age of the vessel to be estimated: older vessels, which have better-developed walls, will show leakage in the mid- to late-stage images, whereas younger vessels will leak between 30 seconds and 1 minute.

The clarity of images taken using these new techniques are such that it is starting to become possible to identify the feeder vessel from a mass of vessels. If the feeder vessel can be identified, fine-needle therapy can be used to block it. Similarly, the Eye Unit is starting to look at vessel structure in papillomas and carcinoma in situ.

In summary, Dr Hodson reiterated that it is important, every time you go to the camera, to remember that every patient is different so your technique might be slightly different. You should keep an open mind how the camera will be positioned, and remember that most patients cannot focus on the bright light. He is now seeing five to six patients every week and demand for the technique is rising.


Dr Martin Hodson, MD


Dr Hodson is senior imaging technician and lead oncology imager at St Paul’s Eye Hospital Liverpool, and world lead in corneal neovascularisation angiography imaging. He is a committee member of the Ophthalmic Imaging Association. He has no conflicts of interest to report with this article.


Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.